Alkem Laboratories Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter

The Alkem Laboratories Q2 results FY27 announcement is the next scheduled earnings event for Alkem Laboratories Ltd., a pharmaceutical company with a large Indian branded generics business in anti-infectives and gastro-intestinal therapies, plus a United States generics operation. The stock traded at Rs 5,181.00 on the NSE on 8 September 2026, down 1.17% from the previous close of Rs 5,242.50, about 12.7% below its 52-week high of Rs 5,933.50 and 2.1% above its 52-week low of Rs 5,075.00.

What makes the Alkem Laboratories Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 4,104.68 crore of revenue and a profit of Rs 779.60 crore, while the most recent quarter on record, Q1 FY27, produced Rs 3,892.90 crore and a profit of Rs 521.49 crore. Everything below is built from those reported figures rather than from any forecast.

Click Here – Get Free Investment Predictions

When Is the Alkem Laboratories Q2 Results FY27 Date?

The Alkem Laboratories Q2 results date for FY27 is not confirmed. As of 8 September 2026, Alkem Laboratories Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.

What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Alkem Laboratories Q2 results date becomes public through that filing rather than through any advance announcement.

The Alkem Laboratories Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Alkem Laboratories.

Alkem Laboratories Q2 Results Expectations: What the Market Is Actually Tracking

No verified analyst estimate for the Alkem Laboratories Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Alkem Laboratories. The Alkem Laboratories Q2 results watchlist below is built from what the company has actually reported and disclosed.

The first is the September 2025 base, which is the strongest of the last five quarters at Rs 4,104.68 crore in revenue and Rs 779.60 crore in profit. The anti-infectives season peaks in that quarter, so it is a demanding comparison by construction.

The second is the profit gap. Q1 FY27 delivered Rs 521.49 crore against Rs 668.32 crore a year earlier on higher revenue, with operating margin of 24.57% against 26.36%, so cost or mix has been working against the company.

The third is the March 2026 quarter, when profit fell to Rs 251.68 crore at a 16.17% margin. That single weak quarter sits inside the trailing twelve months and drags the reported earnings multiple, so it should be understood before drawing conclusions.

Check Alkem Laboratories Ltd. Live Fundamentals on the Univest Screener

Alkem Laboratories Q2 Results Preview: The Q1 FY27 Actuals It Builds On

Alkem Laboratories Ltd. reported revenue of Rs 3,892.90 crore in Q1 FY27, up 10.98% from Rs 3,507.63 crore in Q1 FY26, and a profit of Rs 521.49 crore at the net level, down 21.97% from Rs 668.32 crore in Q1 FY26. These are reported actuals, not estimates.

Sequentially, revenue was up 2.35% over the March 2026 quarter figure of Rs 3,803.39 crore, and net profit was up 107.20% from Rs 251.68 crore in Q4 FY26. Operating margin stood at 24.57% in Q1 FY27 against 25.61% in the September 2025 quarter, which is the comparison the Alkem Laboratories Q2 results print will be read against.

Q2 FY26 Base: The Comparison Alkem Laboratories Q2 Results FY27 Must Beat

Alkem Laboratories Ltd. reported revenue of Rs 4,104.68 crore and a profit of Rs 779.60 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Alkem Laboratories Q2 results preview.

Net profit in that base quarter was above the Rs 521.49 crore just reported for Q1 FY27, so the year-on-year comparison starts from a demanding level. Revenue of Rs 4,104.68 crore sits above the Rs 3,892.90 crore of the June 2026 quarter, which frames how much sequential movement the Alkem Laboratories Q2 results print needs to show growth.

Alkem Laboratories Quarterly Results Trend Over the Last Four Quarters

Quarter	Revenue (Rs Cr)	Net Profit (Rs Cr)
Q2 FY26 (Sep 2025)	4,104.68	779.60
Q3 FY26 (Dec 2025)	3,879.92	653.53
Q4 FY26 (Mar 2026)	3,803.39	251.68
Q1 FY27 (Jun 2026)	3,892.90	521.49

Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company's exchange filings, and they are the only basis this Alkem Laboratories Q2 results preview uses.

Revenue across those four quarters ranged from Rs 3,803.39 crore to Rs 4,104.68 crore, and net profit from Rs 251.68 crore to Rs 779.60 crore. That spread is the honest context for the Alkem Laboratories Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.

Key Factors That Could Shape Alkem Laboratories Q2 Results FY27

The Alkem Laboratories Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Alkem Laboratories has already reported.

Acute Therapy Seasonality

Alkem Laboratories is weighted towards anti-infectives and acute therapies, which sell hardest through the monsoon and post-monsoon months. That makes the September quarter structurally the biggest of the year for this company.

United States Generics Pricing

The American business faces continuous price erosion in generics. Any new launch or approval offsets that, and the balance between the two is what management commentary usually addresses.

Share Price at the Bottom of Its Range

The stock trades at Rs 5,181.00, close to its 52-week low of Rs 5,075.00 and well below both its 50-day average of Rs 5,512.14 and its 200-day average of Rs 5,519.68, with a 14-day RSI of 29.03 in oversold territory.

Alkem Laboratories Q2 Results FY27: Share Price and Valuation Going Into the Print

Alkem Laboratories share price today is Rs 5,181.00 on the NSE, down Rs 61.50 or 1.17% from the previous close of Rs 5,242.50 on 8 September 2026, ahead of the Alkem Laboratories Q2 results announcement.

Metric	Value (8 September 2026)
NSE Symbol	ALKEM
Current Market Price	Rs 5,181.00
52-Week High	Rs 5,933.50
52-Week Low	Rs 5,075.00
Market Capitalisation	Rs 61,935 crore
PE Ratio	28.10
Sector PE	37.70
PB Ratio	4.48
EPS (TTM)	Rs 184.35
Book Value per Share	Rs 1,155.87
Debt to Equity	0.15
Return on Equity	16.66%
50-Day Moving Average	Rs 5,512.14
200-Day Moving Average	Rs 5,519.68
RSI (14)	29.03

The stock trades below both its 50-day average of Rs 5,512.14 and its 200-day average of Rs 5,519.68, with a 14-day RSI of 29.03. None of this is a view on where the shares go once the Alkem Laboratories Q2 results are announced, and no price target is offered here.

Download the Univest iOS App or Univest Android App to track Alkem Laboratories Ltd. live price and quarterly earnings updates.

What Investors Should Watch When Alkem Laboratories Q2 Results Are Announced

Four lines carry most of the information in a company of this size, and reading them in order keeps the Alkem Laboratories Q2 results print in proportion.

1. Revenue against the Rs 4,104.68 crore reported in the September 2025 base quarter
2. Net profit against a profit of Rs 779.60 crore in that same quarter
3. Operating margin against 24.57% in Q1 FY27
4. Any exceptional item, provision or one-off gain disclosed alongside the numbers

A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Alkem Laboratories Q2 results announcement should be read together with the notes to the results rather than the headline alone.

Conclusion on Alkem Laboratories Q2 Results FY27

The Alkem Laboratories Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Alkem Laboratories Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.

On that basis the Alkem Laboratories Q2 results FY27 print faces a base of Rs 4,104.68 crore in revenue and a profit of Rs 779.60 crore, with the most recent quarter having delivered Rs 3,892.90 crore and a profit of Rs 521.49 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Alkem Laboratories, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.

FAQs on Alkem Laboratories Q2 Results FY27

What is the Alkem Laboratories Q2 results date for FY27?

Ans. The Alkem Laboratories Q2 results date for FY27 is not confirmed. Alkem Laboratories Ltd. had not filed a board meeting intimation with the NSE or BSE as of 8 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.

What quarter do the Alkem Laboratories Q2 results 2026 cover?

Ans. The Alkem Laboratories Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Alkem Laboratories Ltd. reports revenue, operating profit and net profit for that period, and the Alkem Laboratories Q2 results filing also carries the notes to the accounts.

What were the Alkem Laboratories Q1 FY27 results?

Ans. Alkem Laboratories Ltd. reported revenue of Rs 3,892.90 crore in Q1 FY27 and a profit of Rs 521.49 crore at the net level. Revenue was up 10.98% versus Q1 FY26 and net profit was down 21.97% from Rs 668.32 crore in Q1 FY26.

What were Alkem Laboratories Q2 FY26 results in the September 2025 quarter?

Ans. Alkem Laboratories Ltd. reported revenue of Rs 4,104.68 crore and a profit of Rs 779.60 crore in Q2 FY26. Operating margin was 25.61%. Those figures form the base for the Alkem Laboratories Q2 results FY27 comparison.

What are the main Alkem Laboratories Q2 results expectations this quarter?

Ans. No verified analyst estimate is publicly available. The Alkem Laboratories Q2 results expectations centre on revenue against the Rs 4,104.68 crore base, net profit against a profit of Rs 779.60 crore, operating margin against 24.57% in Q1 FY27, and any exceptional item disclosed with the numbers.

What is Alkem Laboratories share price today ahead of the Q2 earnings?

Ans. Alkem Laboratories share price is Rs 5,181.00 on the NSE as of 8 September 2026, down 1.17% from Rs 5,242.50. The stock is about 12.7% below its 52-week high of Rs 5,933.50 and 2.1% above its 52-week low of Rs 5,075.00, at a market capitalisation of Rs 61,935 crore.

Is Alkem Laboratories a good stock to buy before the Q2 results?

Ans. This article does not offer a buy, sell or hold recommendation on Alkem Laboratories Ltd.. The stock trades at a price-to-book ratio of 4.48 with a return on equity of 16.66%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.